18793 - Human Photoallergy Test
Human Photoallergy Test
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New Jersey
-
Piscataway, New Jersey, United States, 08854
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be male or female between the ages of 18 and 60 inclusive
- be lightly pigmented (Fitzpatrick Skin Type I, II, III)
- have read and signed the written Informed Consent Form and have completed a HIPAA Authorization Form (Health Insurance Portability and Accountability Act) in conformance with 45CFR Parts 160 and 164
- be in general good health as determined by the subject's medical history and in the discretion of the investigator
Exclusion Criteria:
- have a visible sunburn
- have a history of sun hypersensitivity/photosensitivity or photosensitive dermatoses
- have a known hypersensitivity or allergy against any of the active and non-active ingredients of the investigational products
- subjects who are employees of the CRO (Contract Research Organization) and/or Bayer or is a household member of an employee
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BAY987517
All subjects are patched with the same product
|
One site is patched without treatment as control
50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch.
Twenty-four (24) hours later, the patches are removed.
The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site.
Forty-eight (48) hours later the procedure is repeated to the same test sites.
This process is repeated twice weekly for a total of six exposures.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intensity of skin reactions is evaluated by 5 point scale
Time Frame: Up to 72 hours
|
Up to 72 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18793
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sunscreening Agents
-
NCT05124899Completed
-
NCT03002922Completed
-
NCT05082376Completed
Clinical Trials on Untreated skin
-
NCT00885937Completed